Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter.

Hirao N, Iwata T, Tanaka K, Nishio H, Nakamura M, Morisada T, Morii K, Maruyama N, Katoh Y, Yaguchi T, Ohta S, Kukimoto I, Aoki D, Kawakami Y.

Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31478-7. doi: 10.1016/j.ygyno.2019.08.026. [Epub ahead of print]

PMID:
31477279
2.

Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.

Yin FF, Wang N, Bi XN, Yu X, Xu XH, Wang YL, Zhao CQ, Luo B, Wang YK.

Virol J. 2016 Apr 5;13:60. doi: 10.1186/s12985-016-0515-5.

3.

miR-3156-3p is downregulated in HPV-positive cervical cancer and performs as a tumor-suppressive miRNA.

Xia YF, Pei GH, Wang N, Che YC, Yu FS, Yin FF, Liu HX, Luo B, Wang YK.

Virol J. 2017 Feb 4;14(1):20. doi: 10.1186/s12985-017-0695-7.

4.

HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.

Hu D, Zhou J, Wang F, Shi H, Li Y, Li B.

Arch Gynecol Obstet. 2015 Dec;292(6):1345-54. doi: 10.1007/s00404-015-3787-x. Epub 2015 Jun 21.

PMID:
26093522
5.

Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).

McFarlane M, MacDonald AI, Stevenson A, Graham SV.

J Virol. 2015 May;89(10):5276-87. doi: 10.1128/JVI.03434-14. Epub 2015 Feb 25.

6.
7.

HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.

Yin F, Wang N, Wang S, Yu F, Sun X, Yu X, Luo B, Zhao C, Wang Y.

Oncol Rep. 2017 Apr;37(4):2324-2334. doi: 10.3892/or.2017.5465. Epub 2017 Feb 17.

PMID:
28260046
8.

Conservation of E6 and E7 regions of human papillomavirus types 16 and 18 present in cervical cancers.

Takebe N, Tsunokawa Y, Nozawa S, Terada M, Sugimura T.

Biochem Biophys Res Commun. 1987 Mar 30;143(3):837-44.

PMID:
3032185
9.

RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.

Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, Xu G, Meng L, Lu Y, Wang S, Ma D.

Apoptosis. 2008 Feb;13(2):273-81.

PMID:
18060502
10.

Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells.

He H, Liu X, Liu Y, Zhang M, Lai Y, Hao Y, Wang Q, Shi D, Wang N, Luo XG, Ma W, Zhang TC.

J Virol. 2019 Apr 3;93(8). pii: e01808-18. doi: 10.1128/JVI.01808-18. Print 2019 Apr 15.

11.

Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.

Sato N, Saga Y, Uchibori R, Tsukahara T, Urabe M, Kume A, Fujiwara H, Suzuki M, Ozawa K, Mizukami H.

Int J Oncol. 2018 Mar;52(3):687-696. doi: 10.3892/ijo.2018.4245. Epub 2018 Jan 15.

12.

MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2.

Fujii T, Shimada K, Asano A, Tatsumi Y, Yamaguchi N, Yamazaki M, Konishi N.

Int J Mol Sci. 2016 Aug 18;17(8). pii: E1351. doi: 10.3390/ijms17081351.

13.

Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.

Ding W, Hu Z, Zhu D, Jiang X, Yu L, Wang X, Zhang C, Wang L, Ji T, Li K, He D, Xia X, Liu D, Zhou J, Ma D, Wang H.

Clin Cancer Res. 2014 Dec 15;20(24):6495-503. doi: 10.1158/1078-0432.CCR-14-0250. Epub 2014 Oct 21.

14.
15.

Tobacco Exposure Enhances Human Papillomavirus 16 Oncogene Expression via EGFR/PI3K/Akt/c-Jun Signaling Pathway in Cervical Cancer Cells.

Muñoz JP, Carrillo-Beltrán D, Aedo-Aguilera V, Calaf GM, León O, Maldonado E, Tapia JC, Boccardo E, Ozbun MA, Aguayo F.

Front Microbiol. 2018 Dec 17;9:3022. doi: 10.3389/fmicb.2018.03022. eCollection 2018.

16.

Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.

Zhang HR, Lai SY, Huang LJ, Zhang ZF, Liu J, Zheng SR, Ding K, Bai X, Zhou JY.

Gynecol Oncol. 2018 Apr;149(1):188-197. doi: 10.1016/j.ygyno.2018.01.024. Epub 2018 Feb 1.

PMID:
29395313
17.

Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo.

Zhou J, Peng C, Li B, Wang F, Zhou C, Hong D, Ye F, Cheng X, Lü W, Xie X.

Gynecol Oncol. 2012 Feb;124(2):296-302. doi: 10.1016/j.ygyno.2011.10.028. Epub 2011 Nov 3.

PMID:
22056554
19.

Suppression of HPV E6 and E7 expression by BAF53 depletion in cervical cancer cells.

Lee K, Lee AY, Kwon YK, Kwon H.

Biochem Biophys Res Commun. 2011 Aug 26;412(2):328-33. doi: 10.1016/j.bbrc.2011.07.098. Epub 2011 Jul 29.

PMID:
21821000
20.

A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers.

Yew CW, Lee P, Chan WK, Lim VK, Tay SK, Tan TM, Deng LW.

Cancer Res. 2011 Nov 1;71(21):6696-707. doi: 10.1158/0008-5472.CAN-11-1271. Epub 2011 Sep 9.

Supplemental Content

Support Center